


## GDC-0927

<b>Cat. No.:</b>	HY-111484		
<b>CAS No.:</b>	1642297-01-5		
<b>Molecular Formula:</b>	C <sub>28</sub> H <sub>28</sub> FNO <sub>4</sub>		
<b>Molecular Weight:</b>	462		
<b>Target:</b>	Estrogen Receptor/ERR		
<b>Pathway:</b>	Vitamin D Related/Nuclear Receptor		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 83.33 mg/mL (180.37 mM; Need ultrasonic)					
	<b>Preparing Stock Solutions</b>	<b>Solvent</b>	<b>Mass</b>	<b>1 mg</b>	<b>5 mg</b>	<b>10 mg</b>
		<b>Concentration</b>				
		<b>1 mM</b>		2.1645 mL	10.8225 mL	21.6450 mL
<b>5 mM</b>			0.4329 mL	2.1645 mL	4.3290 mL	
		<b>10 mM</b>		0.2165 mL	1.0823 mL	2.1645 mL
Please refer to the solubility information to select the appropriate solvent.						
<b>In Vivo</b>	<ol style="list-style-type: none"> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 40% PEG300 &gt;&gt; 5% Tween-80 &gt;&gt; 45% saline Solubility: ≥ 2.08 mg/mL (4.50 mM); Clear solution</li> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (4.50 mM); Clear solution</li> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 90% corn oil Solubility: ≥ 2.08 mg/mL (4.50 mM); Clear solution</li> </ol>					

### BIOLOGICAL ACTIVITY

<b>Description</b>	GDC-0927 (SRN-927) is a potent, non-steroidal, orally bioavailable, selective estrogen receptor antagonist <sup>[1]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	Estrogen receptor <sup>[1]</sup>
<b>In Vivo</b>	GDC-0927 is a novel, potent, non-steroidal, orally bioavailable, selective ER antagonist/ER degrader (SERD) that induces tumor regression in estrogen receptor (ER)+breast cancer (BC) patient-derived xenograft models <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

## CUSTOMER VALIDATION

- J Biol Chem. 2022 Nov 29;102757.
- bioRxiv. 2023 Nov 2.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

---

## REFERENCES

[1]. MN Dickler, et al. Abstract PD5-10: A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader (SERD), GDC-0927, in postmenopausal women with estrogen receptor positive (ER+) HER2-negative metastatic breast cancer (BC). AACR;

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA